trending Market Intelligence /marketintelligence/en/news-insights/trending/fdkbpdtmpwbu0sstkluorq2 content esgSubNav
In This List

Private equity firm Sailing Capital invests $30.6M in Cellular Biomedicine

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Private equity firm Sailing Capital invests $30.6M in Cellular Biomedicine

Cellular Biomedicine Group Inc. received a $30.6 million investment from private equity firm Sailing Capital Overseas Investment Ltd. and its affiliates.

As part of the investment, Sailing Capital will appoint a member to the board of Cupertino, Calif.-based Cellular Biomedicine, which develops cell therapies for the treatment of cancer and degenerative diseases.

Cellular Biomedicine noted that the investment will help the prospects of its proprietary technology platform getting approval from the China Food and Drug Administration.

The company's CEO Tony Liu said the investment will also help in funding multiple clinical programs for progressive malignant lymphoma, acute B lymphocytic leukemia and Hodgkin's lymphoma, as well as development in novel T cell receptor therapies.

Cantor Fitzgerald & Co. acted as a financial adviser to Cellular Biomedicine.

Sailing Capital Overseas Investment is focused on China cross-border investments in disruptive global companies in the healthcare, technology and consumer sectors.